Moderna Statistics
Total Valuation
Moderna has a market cap or net worth of $79.16 billion. The enterprise value is $73.54 billion.
| Market Cap | 79.16B |
| Enterprise Value | 73.54B |
Important Dates
The next confirmed earnings date is Friday, November 6, 2026, before market open.
| Earnings Date | Nov 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Moderna has 399.24 million shares outstanding. The number of shares has increased by 1.94% in one year.
| Current Share Class | 399.24M |
| Shares Outstanding | 399.24M |
| Shares Change (YoY) | +1.94% |
| Shares Change (QoQ) | +0.76% |
| Owned by Insiders (%) | 6.74% |
| Owned by Institutions (%) | 80.55% |
| Float | 371.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 35.86 |
| Forward PS | 41.84 |
| PB Ratio | 11.81 |
| P/TBV Ratio | 12.10 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 33.33 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.29, with a Debt / Equity ratio of 0.19.
| Current Ratio | 2.29 |
| Quick Ratio | 2.07 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -58.00 |
Financial Efficiency
Return on equity (ROE) is -39.00% and return on invested capital (ROIC) is -75.99%.
| Return on Equity (ROE) | -39.00% |
| Return on Assets (ROA) | -13.26% |
| Return on Invested Capital (ROIC) | -75.99% |
| Return on Capital Employed (ROCE) | -28.91% |
| Weighted Average Cost of Capital (WACC) | 10.15% |
| Revenue Per Employee | $474,043 |
| Profits Per Employee | -$670,426 |
| Employee Count | 4,700 |
| Asset Turnover | 0.19 |
| Inventory Turnover | 14.23 |
Taxes
In the past 12 months, Moderna has paid $64.00 million in taxes.
| Income Tax | 64.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +601.95% in the last 52 weeks. The beta is 1.09, so Moderna's price volatility has been similar to the market average.
| Beta (5Y) | 1.09 |
| 52-Week Price Change | +601.95% |
| 50-Day Moving Average | 173.63 |
| 200-Day Moving Average | 82.93 |
| Relative Strength Index (RSI) | 46.23 |
| Average Volume (20 Days) | 19,288,279 |
Short Selling Information
The latest short interest is 30.86 million, so 7.73% of the outstanding shares have been sold short.
| Short Interest | 30.86M |
| Short Previous Month | 32.87M |
| Short % of Shares Out | 7.73% |
| Short % of Float | 8.30% |
| Short Ratio (days to cover) | 2.00 |
Income Statement
In the last 12 months, Moderna had revenue of $2.23 billion and -$3.15 billion in losses. Loss per share was -$8.01.
| Revenue | 2.23B |
| Gross Profit | -1.47B |
| Operating Income | -2.44B |
| Pretax Income | -3.09B |
| Net Income | -3.15B |
| EBITDA | -2.20B |
| EBIT | -2.44B |
| Loss Per Share | -$8.01 |
Balance Sheet
The company has $5.14 billion in cash and $1.29 billion in debt, with a net cash position of $5.62 billion or $14.08 per share.
| Cash & Cash Equivalents | 5.14B |
| Total Debt | 1.29B |
| Net Cash | 5.62B |
| Net Cash Per Share | $14.08 |
| Equity (Book Value) | 6.76B |
| Book Value Per Share | 16.94 |
| Working Capital | 3.28B |
Cash Flow
In the last 12 months, operating cash flow was -$1.07 billion and capital expenditures -$171.00 million, giving a free cash flow of -$1.24 billion.
| Operating Cash Flow | -1.07B |
| Capital Expenditures | -171.00M |
| Depreciation & Amortization | 241.00M |
| Net Borrowing | 578.00M |
| Free Cash Flow | -1.24B |
| FCF Per Share | -$3.12 |
Margins
Gross margin is -66.02%, with operating and profit margins of -109.34% and -141.43%.
| Gross Margin | -66.02% |
| Operating Margin | -109.34% |
| Pretax Margin | -138.55% |
| Profit Margin | -141.43% |
| EBITDA Margin | -98.52% |
| EBIT Margin | -109.34% |
| FCF Margin | n/a |
Dividends & Yields
Moderna does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.94% |
| Shareholder Yield | -1.94% |
| Earnings Yield | -4.04% |
| FCF Yield | -1.56% |
Analyst Forecast
The average price target for Moderna is $138.37, which is -30.21% lower than the current price. The consensus rating is "Hold".
| Price Target | $138.37 |
| Price Target Difference | -30.21% |
| Analyst Consensus | Hold |
| Analyst Count | 23 |
| Revenue Growth Forecast (3Y) | 19.80% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Moderna has an Altman Z-Score of 2.62 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.62 |
| Piotroski F-Score | 2 |